ReN 1869

Drug Profile

ReN 1869

Alternative Names: NN 1869; NNC 051869; NNC 1869

Latest Information Update: 08 Oct 2003

Price : $50

At a glance

  • Originator Novo Nordisk
  • Developer ReNeuron
  • Class Analgesics; Anti-inflammatories
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Neuropathic pain; Rheumatic disorders

Most Recent Events

  • 30 Sep 2003 Discontinued - Phase-II for Neuropathic pain in United Kingdom (PO)
  • 30 Sep 2003 Discontinued - Phase-II for Rheumatic disorders in Belgium (PO)
  • 30 Sep 2003 Discontinued - Phase-II for Rheumatic disorders in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top